Spyre Therapeutics(US:SYRE) Globenewswire·2025-10-05 13:00Core Insights - Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing advanced therapies for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases through innovative antibody engineering and therapeutic combinations [1][3] Group 1: Scientific Developments - The company presented follow-up data from a Phase 1 study of SPY002, an anti-TL1A agent, showing it is well tolerated and supports quarterly or biannual dosing, with efficacy in suppressing free TL1A for up to 24 weeks [2] - New preclinical data indicates that combination therapies (α4β7 + TL1A, α4β7 + IL-23, TL1A + IL-23) demonstrate superior efficacy compared to individual monotherapies in rodent models of colitis, supporting ongoing Phase 2 studies [2] Group 2: Pipeline and Future Directions - Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23, aiming to create next-generation treatments for IBD and other immune-mediated diseases [3]